Akt/Nox2/NF-κB signaling pathway is involved in Tat-induced HIV-1 long terminal repeat (LTR) transactivation

被引:18
作者
Zhang, Hong-Sheng [1 ]
Sang, Wei-Wei [1 ]
Ruan, Zheng [1 ]
Wang, Yu-Ou [1 ]
机构
[1] Beijing Univ Technol, Coll Life Sci & Bioengn, Beijing 100124, Peoples R China
基金
北京市自然科学基金;
关键词
Akt; Nox2; Tat; HIV-1; LTR transactivation; NF-KAPPA-B; HUMAN-IMMUNODEFICIENCY-VIRUS; T-CELLS; OXIDATIVE STRESS; DRUG DEVELOPMENT; GENE-EXPRESSION; NADPH OXIDASE; ACTIVATION; TRANSCRIPTION; REPLICATION;
D O I
10.1016/j.abb.2010.10.018
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Human immunodeficiency virus (HIV) regulatory protein Tat has pro-oxidant property, which might contribute to Tat-induced long terminal repeat region (LTR) transactivation. However, the intracellular mechanisms whereby Tat triggers ROS production, and the relationship between Tat-induced ROS production and LTR transactivation, are still subject to debate. The present study was undertaken to evaluate the specific effects of Tat on nicotinamide adenine denucleotide phosphate (NADPH) oxidase in MAGI cells, and to determine the specific role of NADPH oxidase in Tat-induced LTR transactivation. Application of Tat to MAGI cells caused increases in ROS formation that were prevented by both pharmacologic NADPH oxidase inhibitors and by siRNA Nox2, but not by other inhibitors of pro-oxidant enzymes or siRNA Nox4. Furthermore, inhibition of NADPH oxidase by both pharmacologic NADPH oxidase inhibitors and by siRNA Nox2 attenuated Tat-induced p65 phosphorylation and IKK phosphorylation. Phosphatidylinositol 3-kinase/Akt signaling pathway was involved in Tat-induced NADPH oxidase stimulation. Finally, NADPH oxidase inhibitors or Nox2 siRNA, but not control siRNA, inhibited Tat-induced LTR transactivation. Tat-induced HIV-1 LTR transactivation was inhibited in wortmannin or LY294002 treated cells compared to control cells. Together, these data describe a specific and biologically significant signaling component of the MAGI cells response to Tat, and suggest the PI3K/Akt signaling pathway might originate in part with Tat-induced activation of NADPH oxidase and LTR transactivation. (C) 2010 Elsevier Inc. All rights reserved.
引用
收藏
页码:266 / 272
页数:7
相关论文
共 43 条
[1]   Preventing HIV-1 tat-induced neuronal apoptosis using antioxidant enzymes: Mechanistic and therapeutic implications [J].
Agrawal, Lokesh ;
Louboutin, Jean-Pierre ;
Strayer, David S. .
VIROLOGY, 2007, 363 (02) :462-472
[2]   ABSOLUTE DEPENDENCE ON KAPPA-B RESPONSIVE ELEMENTS FOR INITIATION AND TAT-MEDIATED AMPLIFICATION OF HIV TRANSCRIPTION IN BLOOD CD4 T-LYMPHOCYTES [J].
ALCAMI, J ;
DELERA, TL ;
FOLGUEIRA, L ;
PEDRAZA, MA ;
JACQUE, JM ;
BACHELERIE, F ;
NORIEGA, AR ;
HAY, RT ;
HARRICH, D ;
GAYNOR, RB ;
VIRELIZIER, JL ;
ARENZANASEISDEDOS, F .
EMBO JOURNAL, 1995, 14 (07) :1552-1560
[3]   CD28 ligation in the absence of TCR promotes ReIA/NF-κB recruitment and trans-activation of the HIV-1 LTR [J].
Annibaldi, Alessandro ;
Sajeva, Angela ;
Muscolini, Michela ;
Ciccosanti, Fabiola ;
Corazzari, Marco ;
Piacentini, Mauro ;
Tuosto, Loretta .
EUROPEAN JOURNAL OF IMMUNOLOGY, 2008, 38 (05) :1446-1451
[4]   The challenge of viral reservoirs in HIV-1 infection [J].
Blankson, JN ;
Persaud, D ;
Siliciano, RF .
ANNUAL REVIEW OF MEDICINE, 2002, 53 :557-593
[5]   The κB DNA sequence from the HIV long terminal repeat functions as an allosteric regulator of HIV transcription [J].
Chen-Park, FE ;
Huang, DB ;
Noro, B ;
Thanos, D ;
Ghosh, G .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (27) :24701-24708
[6]   Nucleoside and nucleotide HIV reverse transcriptase inhibitors: 25 years after zidovudine [J].
Cihlar, Tomas ;
Ray, Adrian S. .
ANTIVIRAL RESEARCH, 2010, 85 (01) :39-58
[7]   Basal shuttle of NF-κB/IκBα in resting T lymphocytes regulates HIV-I LTR dependent expression [J].
Coiras, Mayte ;
Lopez-Huertas, Maria Rosa ;
Rullas, Joaquin ;
Mittelbrunn, Maria ;
Alcami, Jose .
RETROVIROLOGY, 2007, 4
[8]   NFAT1 enhances HIV-1 gene expression in primary human CD4 T cells [J].
Cron, RQ ;
Bartz, SR ;
Clausell, A ;
Bort, SJ ;
Klebanoff, SJ ;
Lewis, DB .
CLINICAL IMMUNOLOGY, 2000, 94 (03) :179-191
[9]   HIV drug development: the next 25 years [J].
Flexner, Charles .
NATURE REVIEWS DRUG DISCOVERY, 2007, 6 (12) :959-966
[10]  
Gatignol A, 2007, ADV PHARMACOL, V55, P137, DOI 10.1016/S1054-3589(07)55004-0